CHO cells (Chinese Hamster Ovary cells) are mammalian cell lines used to manufacture most modern biologic medicines, including monoclonal antibodies like trastuzumab and rituximab, erythropoietin for anemia, and clotting factors for hemophilia. Isolated from a Chinese hamster ovary in 1957, they now produce roughly seventy percent of approved monoclonal antibodies and a large share of other therapeutic glycoproteins, making them the backbone of biopharmaceutical production.
The sections that follow cover the origin of CHO cells, the engineering methods behind their productivity, the blockbuster drugs they produce, and where the technology is heading next.
A Hamster Ovary Cell That Quietly Took Over Pharma
The story begins in 1957, when a graduate student at the University of Colorado isolated cells from a Chinese hamster ovary. Virologists wanted a reliable mammalian line for studying viruses and chromosomes. Those original cells grew quickly, divided predictably, and tolerated laboratory handling, which made them attractive research tools long before anyone considered drug manufacturing.
From Lab Curiosity to the Genetic Engineering Era
For nearly two decades, these cells remained mostly inside academic laboratories. Recombinant DNA technology in the early 1980s changed everything. Scientists learned how to insert human genes into mammalian cells and then harvest the resulting human proteins. CHO cells proved unusually capable at this. They accept foreign DNA, fold complex proteins into the right shapes, and attach human-compatible sugar structures that determine whether a biologic survives long enough in the bloodstream to actually work.
Bacterial systems such as E. coli cannot perform those modifications at all. Yeast cells come closer but still produce sugar patterns that look foreign to the human immune system. CHO cells land in a practical middle ground. Their protein-folding machinery resembles human cells closely enough that the resulting drugs behave like native human proteins once injected.
The Statistical Reality of CHO Dominance
Those advantages show up clearly in approved drug counts. Industry analyses estimate that roughly seventy percent of approved monoclonal antibodies, plus a large share of other complex therapeutic proteins, are produced in CHO cell lines. That pattern has held for more than two decades, even as alternative hosts like HEK293 and yeast have improved. Teams that already operate a qualified CHO platform rarely switch hosts without strong cause.
| Therapeutic Class | Typical Share Made in CHO | Why CHO Fits |
|---|---|---|
| Monoclonal antibodies | ~70% or more | Human-compatible glycosylation, high yields, scalable |
| Complex glycoproteins (EPO, Factor VIII) | Majority of approved products | Accurate folding and post-translational processing |
| Bispecific antibodies and fusion proteins | Rapidly growing share | Requires careful subunit assembly and stability |
| Recombinant cytokines | Widely used | Correct disulfide bonding and sugar structures |
How CHO Cells Build the Proteins Medicine Actually Needs
Drug development teams choose CHO cells partly for what they make, but mostly for how they make it. The exact modifications a protein carries after leaving the cell often decide whether a biologic is safe, effective, and long-lasting in a patient.
Post-Translational Modifications and Glycosylation
After a cell reads a gene and assembles the protein, an extra layer of work begins. Sugars attach to the protein surface in patterns called glycosylation. Those sugar trees affect how the drug is recognized by immune cells, how long it circulates in the body, and how well it triggers the intended biological effect. CHO cells perform glycosylation that closely resembles human patterns, especially after decades of engineered cell line tweaks. Bacteria cannot glycosylate proteins at all. Yeast cells produce high-mannose sugar chains that the human immune system clears quickly. That difference can be the deciding factor when a protein fails in animal studies or behaves inconsistently in early trials.
Stable Transfection and Gene Amplification
Getting a cell to produce a therapeutic protein requires inserting the gene for that protein and convincing the cell to make large amounts. Two selection systems dominate the field. The DHFR system, short for dihydrofolate reductase, couples the gene of interest to a selectable marker and pushes cells to amplify both genes under methotrexate pressure. The GS system, using glutamine synthetase, achieves amplification through a different selectable marker under methionine sulfoximine selection. Both approaches let developers screen thousands of clones and pick the rare ones that produce commercially relevant yields.
Suspension Growth in Defined Media
Early CHO cultures grew attached to the inside of plastic flasks. Industrial manufacturing demanded something different. Through years of adaptation, modern CHO production lines now grow floating in liquid media inside large stainless-steel bioreactors. Serum-free and chemically defined formulations remove animal-derived components, which simplifies regulatory review and reduces contamination risk. The same cell line that fits a 10-milliliter experiment can scale to 15,000-liter production bioreactors once a clone is qualified.
That scalability is precisely why some of the best-selling biologics of the past two decades were produced in CHO.
Engineered CHO clones can produce multiple grams of antibody per liter of culture, a yield level that makes modern biologic pricing economically feasible.
The Blockbuster Drugs Made Possible by CHO Cells
The clearest way to see why CHO cells matter is to read the drug names. Several of the highest-selling medicines of the past two decades depend on these cells, and the list keeps growing.
Monoclonal Antibodies That Treat Cancer and Autoimmune Disease
Rituximab, marketed as Rituxan, targets CD20 on B cells and treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Trastuzumab, sold as Herceptin, binds HER2-positive breast cancer cells and reshaped treatment for that subtype. Adalimumab, sold as Humira, blocks tumor necrosis factor alpha and treats rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. Denosumab, sold as Prolia and Xgeva, inhibits RANKL and is used for osteoporosis and bone metastases. All four are produced in CHO cells, and all four require human-compatible glycosylation for proper function.
Complex Glycoproteins Beyond Antibodies
Some of the earliest CHO-produced biologics were not antibodies at all. Erythropoietin, a hormone that stimulates red blood cell production, treats anemia in chronic kidney disease and chemotherapy patients. Recombinant Factor VIII treats hemophilia A by replacing the clotting protein that patients lack. Both molecules carry sugar chains that determine how long they survive in circulation, and CHO cells deliver the right structures. Bacterial systems cannot make functional versions of either protein.
Bispecifics, Cytokines, and the Next Wave
Newer formats push CHO capabilities further. Bispecific antibodies carry two different binding domains, which require careful folding and pairing of heavy and light chains. Cytokines such as interleukins and interferons depend on correct disulfide bonding. Fc-fusion proteins, which attach a drug to an antibody fragment to extend half-life, also rely on CHO-compatible processing. As more of these complex formats reach approval, the share of biologics made in CHO continues to grow.
Those blockbuster approvals, in turn, are the clearest evidence of why CHO outcompeted the alternatives.
Why CHO Beat the Competition as an Expression Host
Drug developers did not settle on CHO cells by accident. They compared it against every available alternative and chose it for specific reasons tied to safety, scale, and product quality.
Side-by-Side Comparison of Common Expression Hosts
| Host | Best For | Glycosylation Match to Human | Scalability |
|---|---|---|---|
| CHO cells | Complex antibodies, glycoproteins, Fc-fusions | Close (human-compatible) | High, industry-proven |
| HEK293 cells | Viral vectors, transient expression, some complex proteins | Close (human) | Moderate |
| E. coli | Simple, non-glycosylated proteins, antibody fragments | None | Very high |
| Yeast (Pichia, Saccharomyces) | Industrial enzymes, some vaccines | Poor (high-mannose) | High |
| Insect cells (Sf9, High Five) | Vaccines, structural biology, some enzymes | Partial | Moderate |
CHO cells dominate the antibody space because they score highest across yield, product quality, and regulatory acceptance. HEK293 cells, derived from human embryonic kidney, remain popular for viral vector production and transient expression experiments but appear less often in large-scale commercial bioreactors. E. coli excels at cheap, fast production of simple proteins like insulin and antibody fragments but cannot manufacture glycosylated biologics. Yeast systems offer low cost and rapid growth but produce sugar structures that limit therapeutic use.
Viral Safety and Regulatory Acceptance
Regulators approving injectable biologics worry about contamination with viruses that could infect patients. CHO cells originate from rodents, not humans, so they are unlikely to harbor human-tropic viruses. Decades of accumulated manufacturing data and a deep understanding of CHO cell biology make regulatory submissions faster and lower risk. Contract development organizations such as Lonza, WuXi Biologics, and Thermo Fisher Scientific have built entire business models around CHO-based manufacturing, which lowers the barrier for new entrants.
Decades of Accumulated Process Knowledge
Every approved CHO-based biologic adds to a shared body of knowledge. Media formulations, feeding strategies, and purification methods have all been refined through years of trial and error. New programs build on that foundation rather than starting from scratch. That accumulated know-how is a quiet but powerful advantage that newer hosts struggle to match.
Beyond Antibodies: Emerging and Non-Traditional Uses
CHO cells were once thought of strictly as antibody factories. That view has expanded considerably. The same protein-folding accuracy and human-compatible processing now support a wider set of applications.
Viral Vectors, Vaccines, and Gene Therapy Components
Some vaccine antigens and gene therapy constructs require mammalian cell-based production to display the right surface structures. CHO-produced vaccine antigens are in development for several hard-to-target pathogens. Viral vector components for cell and gene therapies sometimes use CHO-derived helper plasmids or envelope proteins. Even when the final vector is made in HEK293 cells, CHO-derived components can play supporting roles in the manufacturing chain.
Engineered Enzymes, Exosomes, and Research Reagents
Rare disease research increasingly relies on CHO cells to produce replacement enzymes for conditions like Pompe disease and Fabry disease. Exosomes and other extracellular vesicles, now studied as drug delivery vehicles, are often produced in CHO lines because of their consistency. Diagnostic proteins used in clinical assays also depend on CHO-based production when human-compatible glycosylation matters for antibody recognition.
Regulatory Testing Assays
CHO cells serve a second role in quality control. Regulatory agencies require genotoxicity and cytotoxicity testing for many drug substances, and CHO-derived reporter cell lines are standard tools in those assays. The same cell biology that makes CHO useful for production also makes it predictable in standardized safety tests.
Yet that same predictability exposes limitations when researchers ask CHO to do things antibodies never demanded.
Known Limits and the Push Toward Next-Generation Hosts
CHO cells are not perfect. The pharmaceutical industry continues to invest in alternatives precisely because some limitations matter for specific products.
Glycosylation Differences from Human Cells
Even with decades of engineering, CHO glycosylation is not identical to human glycosylation. Certain sugar structures, such as alpha-1,3-galactose and N-glycolylneuraminic acid, are absent from humans but can appear on CHO-produced proteins. Those differences can trigger immune responses in some patients or alter drug clearance. Glycoengineered CHO lines have closed much of the gap, but the underlying biology remains rodent-derived.
Cost, Timeline, and Clonal Drift
Bringing a new CHO production line from a single transfected cell to a qualified commercial clone can take years and significant capital. Media costs, bioreactor time, and regulatory testing add up. Even after launch, clonal drift, in which a cell line gradually changes over many generations, requires ongoing stability studies. For products that need to reach market quickly or for smaller patient populations, simpler expression systems sometimes make more sense.
The Viral Contamination History That Still Shapes Rules
CHO cells themselves carry low risk of human viruses, but historical contamination events in other mammalian cell lines shaped modern biosafety standards. Viral clearance steps, raw material sourcing rules, and facility segregation requirements all trace back to past incidents. Newer platforms such as HEK293, fully human cell lines, and even cell-free expression systems are partly attractive because they avoid some of those legacy concerns.
Where Next-Generation Hosts Are Gaining Ground
HEK293-derived lines lead viral vector production and certain complex proteins. Human cell lines, including those derived from retinal or hepatic origins, are being explored for products where human-identical glycosylation matters most. Cell-free expression systems, which use purified cellular machinery rather than living cells, are emerging for niche applications like personalized cancer vaccines and rapid-response pandemic production. None of these platforms is positioned to displace CHO for mainstream antibody manufacturing, but each is claiming real space in adjacent fields.
The Bottom Line
CHO cells turned a 1957 laboratory observation into the foundation of modern biologic medicine. Their ability to fold complex proteins, add human-compatible sugar structures, scale to industrial bioreactors, and pass regulatory scrutiny has made them the default choice for monoclonal antibodies and a growing list of other therapeutics. The same technology now supports vaccines, gene therapy components, and diagnostic reagents, while next-generation hosts chip away at specific niches. For most new biologics today, the answer to what are CHO cells used for starts with the drug name on the label.
FAQ
What are CHO cells used for in the pharmaceutical industry?
CHO cells manufacture complex biologic drugs, especially monoclonal antibodies, therapeutic glycoproteins, fusion proteins, and certain vaccine antigens. They are the dominant mammalian host for producing injectable recombinant therapeutics approved by regulators.
Why are CHO cells preferred for producing monoclonal antibodies?
CHO cells produce antibodies with human-compatible glycosylation patterns, fold complex multi-chain proteins accurately, grow in serum-free suspension culture, and scale to industrial bioreactors. Decades of accumulated process knowledge and low viral contamination risk also make them the safest choice for commercial antibody production.
What percentage of approved biologics are produced in CHO cells?
Roughly seventy percent of approved monoclonal antibodies are produced in CHO cell lines. The share runs similarly high across other complex glycoproteins, and CHO remains the default host for most new antibody programs entering clinical development.
What therapeutic proteins are made in CHO cells?
Four of the most widely prescribed monoclonal antibodies, rituximab, trastuzumab, adalimumab, and denosumab, are produced in CHO cells. Erythropoietin for anemia, Factor VIII for hemophilia, and various cytokines and Fc-fusion proteins are also CHO-produced therapeutics that cannot be reliably manufactured in bacterial systems.
How are CHO cells used in vaccine and biologics manufacturing?
CHO cells produce recombinant vaccine antigens that require mammalian folding and glycosylation. They also manufacture certain viral vector components, exosomes, engineered enzymes, and diagnostic proteins. In regulatory testing, CHO-derived reporter lines support genotoxicity and cytotoxicity assays required for drug approval.
